Diabetic Proteinuria Revisited: Updated Physiologic Perspectives
Samuel N. Heyman(Herzog Hospital), Zaid Abassi(Technion – Israel Institute of Technology), Roni Weinberg Sibony(Rabin Medical Center), Julia B. Lewis, Jamie P. Dwyer(University of Utah), Itamar Raz(Hebrew University of Jerusalem)
Cited by 51
Related Papers
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2
|American Journal of Kidney Diseases|2010|599
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|The Lancet Diabetes & Endocrinology|2019|372
Overview of oxidative stress and inflammation in diabetes
|Journal of Diabetes|2024|216